PubMed Health⌕ Search

Biomedical subjects

H Takasu

Publications and source records attributed to H Takasu.

22 records · Page 2Linked to original sources
PubMed1990

An active site of growth hormone for eliciting the differentiation of preadipose 3T3-F442A cells to adipose cells.

In order to elucidate the active sites of growth hormone for eliciting the differentiation of preadipose 3T3-F442A cells to adipocytes, four artificial mutant variants of human growth hormone (hGH) modified in the loop region of amino acid residues 54-74 were prepared in Escherichia coli by site-directed mutagenesis. Although the P59A (replacement of Pro59 with Ala) variant retained almost the same biological- and receptor binding-activity as hGH, the P61A (replacement of Pro61 with Ala) and the P59A-P61A (replacement of both Pro59 and Pro61 with Ala) both exhibited about half the activity, and the delta (62-67) variant (deletion of the residues 62-67) exhibited only about 0.1% the activity of those of intact hGH. The results suggest that Pro61 may be involved in formation of the active conformation of hGH, but Pro59 may not, and that the amino acid residues around 62-67 may be critical for the specific biological features of hGH.

Adipose Tissue↗
PubMed1975

Inflammation of the skin. I. Phospholipid metabolism in some experimental inflammations of mouse skin.

Phospholipid metabolism in inflamed tissue of the mouse skin which had been induced by the application of 1-chloro-2, 4-dinitrobenzene (DNCB), croton oil, or irradiation of ultraviolet rays was examined, and it was found that phospholipid levels had increased in theinflamed tissues. In the case of ultraviolet rays, the increase was temporary, and the level returned to that of control after 3 or 4 days. In the case of DNCB or croton oil, the level increased after a decrease for a short period. The pattern of the increase between physical and chemical irritation was different. Increase of incorporation of 32-P into phospholipid in inflamed tissue was examined, and it was observed that the level reached a maximum after one day. It is thus assumed that phospholipid plays an important role in the mechanism of inflammation.

Animals↗
PubMedDate not supplied

Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium.

A clinical trial of once-daily administration of a 125-mg tablet of terbinafine, an oral antimycotic agent, was performed on patients with tinea unguium to evaluate its efficacy, safety, possible side-effects and its incorporation into nails and hair. Thirty-four patients were recruited into the study. For the statistical analysis, one of these patients was used only for the safety rating. Accordingly, 33 patients were used for the efficacy rating, and all 34 patients were employed for the safety rating. The efficacy rating in the overall efficacy evaluation was 90.9% (30/33). No adverse effects, including abnormal changes in laboratory test values, were observed. A pharmacokinetic study revealed that terbinafine was detected in the nail tissue at and after week 2. It reached 0.78 ng mg-1 at the end of week 12 and remained at almost the same level thereafter. Terbinafine was also detected in hair at and after week 23. The average value was 3.14 ng mg-1. The plasma concentration of the drug reached a steady state (280.3 ng ml-1) at approximately week 10, and no tendency to further accumulation was noted. These results confirm the favourable incorporation of terbinafine into nail and hair. On the basis of these results, it was concluded that the drug demonstrates excellent efficacy and satisfactory safety in patients with tinea unguium. The pharmacokinetic investigation also demonstrated its excellent treatment efficacy.

Administration, Oral↗